Lee M Ocuin1, Jennifer L Miller-Ocuin1, Stephanie M Novak1, David L Bartlett1, J Wallis Marsh2, Allan Tsung2, Kenneth K Lee1, Melissa E Hogg1, Herbert J Zeh1, Amer H Zureikat3. 1. Division of Surgical Oncology, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 2. Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 3. Division of Surgical Oncology, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Electronic address: zureikatah@upmc.edu.
Abstract
BACKGROUND: Distal pancreatectomy with celiac axis resection (DP-CAR) is an option for T4 tumors of the pancreatic body. We examined the perioperative and oncologic outcomes of open and robotic DP-CAR at a high-volume pancreatic center. METHODS: Retrospective review of all consecutive DP-CARs. Patient demographics, 90-day perioperative outcomes, and disease specific survival were collected. RESULTS: 30 DP-CARs were performed (11 Robotic, 19 Open). Both groups had similar preoperative/tumor characteristics, and 27 of 28 PDA patients received neoadjuvant chemotherapy. Robotic DP-CAR was associated with decreased OT (316 vs. 476 min), reduced EBL (393 vs. 1736 ml) and lower rates of blood transfusion (0% vs. 54%) (all p < 0.05). No robotic DP-CAR required conversion. Both groups had similar rates of 90-day mortality, major morbidity, LOS, readmission, and receipt of adjuvant therapy. Similarly, both approaches were associated with high R0 resection rates (82% vs. 79%). At a median follow-up of 33 months, median overall survival for the PDA cohort was 35 months, with no difference in the robotic and open approach (33 and 40 months, p = 0.310). CONCLUSIONS: With a median survival approaching 3 years, DP-CAR represents an effective treatment for select patients with locally advanced pancreatic body cancer, regardless of approach.
BACKGROUND: Distal pancreatectomy with celiac axis resection (DP-CAR) is an option for T4 tumors of the pancreatic body. We examined the perioperative and oncologic outcomes of open and robotic DP-CAR at a high-volume pancreatic center. METHODS: Retrospective review of all consecutive DP-CARs. Patient demographics, 90-day perioperative outcomes, and disease specific survival were collected. RESULTS: 30 DP-CARs were performed (11 Robotic, 19 Open). Both groups had similar preoperative/tumor characteristics, and 27 of 28 PDA patients received neoadjuvant chemotherapy. Robotic DP-CAR was associated with decreased OT (316 vs. 476 min), reduced EBL (393 vs. 1736 ml) and lower rates of blood transfusion (0% vs. 54%) (all p < 0.05). No robotic DP-CAR required conversion. Both groups had similar rates of 90-day mortality, major morbidity, LOS, readmission, and receipt of adjuvant therapy. Similarly, both approaches were associated with high R0 resection rates (82% vs. 79%). At a median follow-up of 33 months, median overall survival for the PDA cohort was 35 months, with no difference in the robotic and open approach (33 and 40 months, p = 0.310). CONCLUSIONS: With a median survival approaching 3 years, DP-CAR represents an effective treatment for select patients with locally advanced pancreatic body cancer, regardless of approach.
Authors: Murtaza Shakir; Brian A Boone; Patricio M Polanco; Mazen S Zenati; Melissa E Hogg; Allan Tsung; Haroon A Choudry; A James Moser; David L Bartlett; Herbert J Zeh; Amer H Zureikat Journal: HPB (Oxford) Date: 2015-04-23 Impact factor: 3.647
Authors: David A Kooby; William G Hawkins; C Max Schmidt; Sharon M Weber; David J Bentrem; Theresa W Gillespie; Johnita Byrd Sellers; Nipun B Merchant; Charles R Scoggins; Robert C G Martin; Hong Jin Kim; Syed Ahmad; Clifford S Cho; Alexander A Parikh; Carrie K Chu; Nicholas A Hamilton; Courtney J Doyle; Scott Pinchot; Amanda Hayman; Rebecca McClaine; Attila Nakeeb; Charles A Staley; Kelly M McMasters; Keith D Lillemoe Journal: J Am Coll Surg Date: 2010-05 Impact factor: 6.113
Authors: Cristina R Ferrone; Giovanni Marchegiani; Theodore S Hong; David P Ryan; Vikram Deshpande; Erin I McDonnell; Francesco Sabbatino; Daniela Dias Santos; Jill N Allen; Lawrence S Blaszkowsky; Jeffrey W Clark; Jason E Faris; Lipika Goyal; Eunice L Kwak; Janet E Murphy; David T Ting; Jennifer Y Wo; Andrew X Zhu; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-del Castillo Journal: Ann Surg Date: 2015-01 Impact factor: 12.969
Authors: Marlo Blazer; Christina Wu; Richard M Goldberg; Gary Phillips; Carl Schmidt; Peter Muscarella; Evan Wuthrick; Terrence M Williams; Joshua Reardon; E Christopher Ellison; Mark Bloomston; Tanios Bekaii-Saab Journal: Ann Surg Oncol Date: 2014-10-31 Impact factor: 5.344
Authors: U Boggi; S Signori; N De Lio; V G Perrone; F Vistoli; M Belluomini; C Cappelli; G Amorese; F Mosca Journal: Br J Surg Date: 2013-06 Impact factor: 6.939
Authors: Sjors Klompmaker; Jony van Hilst; Sarah L Gerritsen; Mustapha Adham; M Teresa Albiol Quer; Claudio Bassi; Frederik Berrevoet; Ugo Boggi; Olivier R Busch; Manuela Cesaretti; Raffaele Dalla Valle; Benjamin Darnis; Matteo De Pastena; Marco Del Chiaro; Robert Grützmann; Markus K Diener; Traian Dumitrascu; Helmut Friess; Arpad Ivanecz; Anastasios Karayiannakis; Giuseppe K Fusai; Knut J Labori; Carlo Lombardo; Santiago López-Ben; Jean-Yves Mabrut; Willem Niesen; Fernando Pardo; Julie Perinel; Irinel Popescu; Geert Roeyen; Alain Sauvanet; Raj Prasad; Christian Sturesson; Mickael Lesurtel; Jorg Kleeff; Roberto Salvia; Marc G Besselink Journal: Ann Surg Oncol Date: 2018-03-12 Impact factor: 5.344